Sentences with word «infliximab»

The pilot observational study of 48 patients found proactive monitoring of infliximab concentrations resulted in a significantly better chance of continuing on therapy than in patients who received the standard treatment and dosing regimen.

For this multicenter retrospective study, Cheifetz and colleagues analyzed the long - term outcomes of 264 patients with IBD on infliximab maintenance at either BIDMC or University of Pennsylvania hospitals, just under half of whom were monitored proactively.

The first infliximab biosimilar in Europe is marketed under two brand names: Inflectra (made by Hospira) and Remsima (made by Mundipharma).

Up to half of patients who benefit from the first - line anti-inflammatory drug infliximab eventually stop responding to it.

Biopharmaceuticals (or «biologics»), such as infliximab, have revolutionised the treatment of many rheumatic diseases.

These results are aligned with previous infliximab antibody data among patients with inflammatory bowel diseases being treated with Remicade.

In 2009, with that standard in mind, BIDMC attending physician Adam S. Cheifetz, MD began monitoring infliximab levels in his IBD patients with the goal of gradually adjusting their dosing regimens to hopefully improve long - term efficacy and decrease toxicity.

In pursuit of the inflammation - depression connection, researchers from Emory University in Atlanta looked at the use of an anti-inflammatory drug called infliximab for the treatment of major depression in people who had not responded to antidepressants.

Therefore, in patients where biological infliximab is ineffective due to the presence of circulating antibodies, switching to its biosimilar will lead to the same problems,» Dr Nagore concluded.

The authors hypothesize that maintaining a target infliximab concentration prevents the formation of antibodies to the therapy, which are implicated in loss of response to the drug and infusion reactions.

Some patients eventually develop antibodies against infliximab and need to switch medications.

Published in the Journal of Experimental Medicine online Oct. 31, the new study found that infliximab prevents TNF alpha from speeding the death of Paneth cells, which protect the gut from microbes.

Now, a team led by gastroenterologists at the Center for Inflammatory Bowel Diseases at Beth Israel Deaconess Medical Center (BIDMC) and University of Pennsylvania, has shown that monitoring patients treated with infliximab prior to loss of patient response to the drug is associated with better long - term outcomes than monitoring the drug only after it loses efficacy.

«In our study, patients who did not have proactive monitoring were three times more likely to stop infliximab.

However, the incidence of the ADA and their magnitude of impact on the clinical response or adverse event were similar between biosimilar CT - P13 and innovator infliximab.

«Biosimilar CT - P13 matches infliximab in improving ankylosing spondylitis disease activity.»

«Currently physicians are not routinely checking infliximab levels,» said Cheifetz, Director of Center for Inflammatory Bowel Disease at BIDMC and an Associate Professor of Medicine at Harvard Medical School.

«Prolonging infliximab's efficacy and avoiding surgery and hospitalization is very important for patients with IBD,» said Cheifetz.

Of 21 adverse reactions registered, seven were considered severe (anaphylactic reactions on infliximab infusion).

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment has been reported >

The study, published in the Inflammatory Bowel Disease Journal, evaluated the levels of infliximab, an antibody designed to bind to and block the effects of TNF - alpha, an inflammatory protein found in high levels in patients with IBD, such as Crohn's disease and ulcerative colitis, and numerous other inflammatory conditions such as rheumatoid arthritis and psoriasis.

A recent analysis of clinical trials shows that anti-tumour necrosis factor a (anti-TNF) agents such as infliximab and adalimumab are much more effective than placebo at maintaining mucosal healing in Crohn's disease (28 % versus 1 %).

Clinicians had previously assumed it was a culprit in NIV, yet infusions of an anti-TNFalpha drug called infliximab hadn't alleviated symptoms for patients with the disease.

«Proactive monitoring is the standard of care in my practice and that of [co-senior author] Mark Osterman, MD, and I think it would benefit the vast majority of patients on infliximab and similar biologic medications.»

Researchers at NYU School of Medicine found that the value of the drug infliximab, marketed as Remicade, in both applications proceeds from its ability to block the contribution of the protein tumor - necrosis factor alpha, or TNF alpha, to problem - causing inflammation.

Dr. Brian Feagan, CEO and Senior Scientific Director of Robarts Clinical Trials and a professor in the Division of Gastroenterology at Western's Schulich School of Medicine & Dentistry, says the medical management of Crohn's disease has undergone important changes over the past two decades with the introduction of TNF antagonists such as adalimumab and infliximab.

Many existing drugs for rheumatoid arthritis are expensive protein therapies, such as the blockbuster antibody drug Remicade (infliximab), marketed in the United States by Centocor of Horsham, Penn., which earned about $ 6 billion in global sales in 2009.

Some approved Crohn's drugs such as adalimumab (Humira) and infliximab (Remicade) block TNF - alpha directly by binding to it.

«The Food and Drug Administration (FDA) has announced the approval of Inflectra (infliximab - dyyb), the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis.

ew data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly - approved infliximab biosimilar CT - P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).

«Biosimilar switching not suitable for all patients: Patients with antibodies to biological infliximab are less likely to benefit from infliximab biosimilar (CT - P13).»

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that when antibodies develop in response to the biological treatment Remicade ® (infliximab), they also cross-react with the biosimilar of infliximab (CT - P13: Inflectra ® or Remsima ®).

Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient's chances of having a long - term successful response to therapy, a pilot observational study at Beth Israel Deaconess Medical Center concludes.

Of those, only 13 percent of patients experienced a treatment failure — defined as loss of response to infliximab or need for IBD - related surgery.

Additionally, it is estimated that 10 percent of patients on infliximab will lose response to the drug each year.

More commonly known as Remicade, infliximab is one of four anti-TNF agents used to treat these inflammatory diseases when they do not respond to or are intolerant of conventional therapies.

Only two - thirds of patients initially respond to infliximab and at one year less than half of the patients remain in remission.

He was treated with high - dose glucocorticoids and infliximab, but eventually complete heart block developed and supportive care was withdrawn.

This is shiny new technology, and it's used to manufacture the three drugs that pharmaceutical forecasters predict will be this year's top - selling medicines — the monoclonal antibody drugs Humira (adalimumab) and Remicade (infliximab), and Enbrel (etanercept), another kind of biologic known as an Fc fusion protein.

The major players in the arthritis drug market include Remicade ® (infliximab), Humira ® (adalimumab), Enbrel ® (etanercept), Cimzia ® (certolizumab pegol) and Simponi ® (golimumab), while biosimilars of the above as well as new drugs with novel mechanisms of action are under development.

May 21, 2000 Study shows infliximab can maintain long - term remissions in Crohn's disease Periodic treatment with the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease.

After moving to Florida, I found a great gastroenterologist who put me on a drug called Remicade (infliximab).

Other biologics include Amevive (alefacept), Enbrel (etanercept), Remicade (infliximab), Simponi (golimumab), and Stelara (ustekinumab).

Examples of these medications used to treat Crohn's disease include: adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia) and ustekinumab (Stelara), according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

In one recent trial, 9 a subset of patients resistant to antidepressant treatment and identified by serum markers of inflammation, most notably C - reactive protein > 3mg / L, were responsive to treatment with the TNF - alpha antagonist (anti-inflammatory) infliximab (Remicade).

• NSAIDs such as ibuprofen (Advil and Motrin) and naproxen (Aleve) • Corticosteroids • DMARDs such as methotrexate (Trexall) and leflunomide (Arava) • Biologic therapies (TNF - alpha blockers) such as adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade • Immunosuppressants such as cyclosporine (Neoral, Gengraf, Sandimmune) and azathioprine (Imuran)

Treatment involves topical treatments (cortisone creams, coal tar or anthralin containing creams, moisturizers, vitamin D and vitamin A), novel systemic immunosuppressant drugs (e.g. etanercept, infliximab, etc.) and phototherapy.

The drug, known as «infliximab» (Remicade), reduces levels of a protein called «tumor necrosis factor alpha», which is believed to contribute to the inflammation of Crohn's disease.

(2) Hospira has brought an impeachment action and a declaration of non-infringement against an infliximab patent (which is listed in respect of Janssen's REMICADE).